Verdence Capital Advisors LLC Purchases 1,217 Shares of Cencora, Inc. (NYSE:COR)

Verdence Capital Advisors LLC grew its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 4.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,853 shares of the company's stock after purchasing an additional 1,217 shares during the period. Verdence Capital Advisors LLC's holdings in Cencora were worth $8,302,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Net Worth Advisory Group boosted its position in Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares during the last quarter. Cromwell Holdings LLC increased its position in shares of Cencora by 9.5% during the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after purchasing an additional 39 shares during the last quarter. Whittier Trust Co. raised its stake in shares of Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. Private Trust Co. NA boosted its holdings in shares of Cencora by 2.5% in the 1st quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock valued at $538,000 after buying an additional 47 shares during the last quarter. Finally, Permanent Capital Management LP grew its stake in shares of Cencora by 4.0% in the first quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock valued at $344,000 after buying an additional 48 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

COR traded down $1.65 on Friday, reaching $292.73. The stock had a trading volume of 1,049,106 shares, compared to its average volume of 1,504,049. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The company has a market capitalization of $56.74 billion, a price-to-earnings ratio of 33.96, a price-to-earnings-growth ratio of 1.48 and a beta of 0.57. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The firm has a 50-day moving average of $292.19 and a 200-day moving average of $271.61.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.80 earnings per share. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Analyst Ratings Changes

COR has been the topic of several analyst reports. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, Robert W. Baird upped their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $309.83.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer owned 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock valued at $9,812,296 in the last ninety days. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.